Immobilized Recombinant Human IL-18 Bpa Protein (rp169678) at 2.0 μg/mL can bind Recombinant Human IL-18 Protein (rp186564) with the EC50 of 30.0 ng/mL. Immobilized Recombinant IL-18 protein (rp186564) at 1.0 μg/mL can bind Camoteskimab (anti-IL-18) (Ab182692) with the EC50 of 400.2 ng/mL.
Interleukin-18 (IL-18, also known as interferon-gamma inducing factor) is a proinflammatory cytokine that belongs to the IL-1 superfamily and is produced by macrophages and other cells. This cytokine can induce the IFN-gamma production of T cells. The combination of IL-18 and IL12 has been shown to inhibit IL4 dependent IgE and IgG1 production, and enhance IgG2a production of B cells. IL-18 binding protein (IL18BP) can specifically interact with this cytokine, and thus negatively regulate its biological activity. IL-18 is an IL-1-like cytokine that requires cleavage with caspase-1 to become active, was found to increase IgE production in a CD4+ T cell -, IL-4- and STAT6-dependent fashion. IL-18 and T cell receptor-mediated stimulation could induce naive CD4+ T cells to develop into IL-4-producing cells in vitro. Thus, caspase-1 and IL-18 may be critical in the regulation of IgE production in vivo, providing a potential therapeutic target for allergic disorders. IL-18 production in primary synovial cultures and purified synovial fibroblasts was, in turn, upregulated by TNF-α and IL-1β, suggesting that monokine expression can feedback to promote Th1 cell development in the synovial membrane. Besides, synergistic combinations of IL-18, IL-12, and IL-15 may be of importance in sustaining both Th1 responses and monokine production in RA.
Post-translational: The pro-IL-18 precursor is processed by CASP1, CASP4 or CASP5 to yield its mature, active form. The pro-IL-18 precursor features autoinhibitory interactions between the propeptide and the post-cleavage-site region, preventing recognition by the IL18R1 receptor. Processing by CASP1, CASP4 or CASP5 induces conformational changes to generate critical receptor-binding sites. The mature form is then secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore.
In contrast, cleavage by CASP3 inactivates IL18.
生物活性
Immobilized Recombinant Human IL-18 Bpa Protein (rp169678) at 2.0 μg/mL can bind Recombinant Human IL-18 Protein (rp186564) with the EC50 of 30.0 ng/mL. Immobilized Recombinant IL-18 protein (rp186564) at 1.0 μg/mL can bind Camoteskimab (anti-IL-18) (Ab182692) with the EC50 of 400.2 ng/mL.
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 0.5 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
Store at -20°C for 1 year. Avoid freeze/thaw cycle.
图片
Recombinant Human IL-18 Protein (rp186564) - Binding Activity Immobilized Recombinant Human IL-18 Bpa Protein (rp169678) at 2.0 μg/mL can bind Recombinant Human IL-18 Protein (rp186564) with the EC
₅₀
of 30.0 ng/mL.
Recombinant Human IL-18 Protein (rp186564) - Binding Activity Immobilized Recombinant IL-18 protein (rp186564) at 1.0 μg/mL can bind Camoteskimab (anti-IL-18) (Ab182692) with the EC
₅₀
of 400.2 ng/mL.
Recombinant Human IL-18 Protein (rp186564) - SDS-PAGE 3 μg/lane of Recombinant Human IL-18 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 15.7 kDa.
ZJ25F1028478
危险品化学品经营许可证（带存储）